海南医学院学报2023，Vol.29Issue(24)：1914-1920,7.DOI:10.13210/j.cnki.jhmu.20230330.004
核输出蛋白XPO1抑制剂治疗血液肿瘤最新进展
Recent progresson nuclear export protein XPO1 inhibitor in the treatment of hematological malignancies
摘要
Abstract
Most tumor suppressor and growth-regulating proteins are transported via the plasmic nuclear transporter expor-tin 1(XPO1).Many malignancies have excessive XPO1 expression,which is associated with disease progression and resistance to therapy.A novel class of anticancer medication called selective inhibitor of nuclear export(SINE)can down-regulate the levels of a number of antigenic proteins in the cytoplasm,activate tumor suppressor and other growth regulating proteins,and promote the nuclear retention and apoptosis of tumor cells.This article discusses the function of XPO1 in drug resistance and tumor develop-ment as well as the advancement of XPO1 inhibitor research for the treatment of hematological cancers.关键词
核输出蛋白1/Selinexor/血液肿瘤/临床试验Key words
Exportin-1/Selinexor/Hematologic malignancies/Clinical trials分类
医药卫生引用本文复制引用
高娅娅,李宏,高广勋..核输出蛋白XPO1抑制剂治疗血液肿瘤最新进展[J].海南医学院学报,2023,29(24):1914-1920,7.基金项目
This study was supported by National Natural Science Foundation Project(81970190) （81970190）
Shaanxi Provincial Social Development Public Relations Key Project(2019ZDLSF02-02) （2019ZDLSF02-02）
National Medical Center Transformation Project(2020ZKMC01) 国家自然科学基金项目(81970190) （2020ZKMC01）
陕西省社发公关重点项目(2019ZDLSF02-02) （2019ZDLSF02-02）
国家医学中心转化课题(2020ZKMC01) （2020ZKMC01）
